The effectiveness of Cempra Inc’s antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday. The panel voted 7-6 that the drug, solithromycin, should be approved to treat the kind of pneumonia that recently affected U.S. presidential candidate Hillary Clinton. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so.
Here is the original:
U.S. FDA panel narrowly backs Cempra’s antibiotic solithromycin
